# Adjunctive Everolimus Treatment of Refractory Epilepsy

> **NCT05613166** · PHASE2 · UNKNOWN · sponsor: **National Institute on Drug Dependence, China** · enrollment: 108 (estimated)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05613166
- **Lead sponsor:** National Institute on Drug Dependence, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11
- **Primary completion:** 2023-01
- **Final completion:** 2023-03
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2022-11-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05613166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05613166, "Adjunctive Everolimus Treatment of Refractory Epilepsy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05613166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*